Epilepsy is a heterogeneous condition requiring individualized treatment, and a substantial number of patients are treatment-refractory. Neurologists consider many factors when selecting an antiepileptic drug (AED) and must make adjustments throughout the patient’s disease course to achieve optimal seizure control. Understanding the evolving patient journey in epilepsy provides important context about the complex, saturated, and heavily generic market that developers of new AEDs will enter. We provide national patient-level claims data that show the use of key therapies in both newly diagnosed and recently treated patients, line of therapy progression, and persistence and compliance by brand.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis.
Key companies: GW Pharmaceuticals, Eisai, Supernus Pharmaceuticals, Upsher-Smith, UCB, Sunovion, Pfizer.
Key drugs covered: Xcopri, Fintepla, Vimpat, Aptiom, Briviact, Epidiolex, Fycompa, Lyrica, levetiracetam, lamotrigine, carbamazepine and oxcarbazepine.
Key analysis provided:
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.